Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer
Heather Greenlee,Lynda G Balneaves,Linda E Carlson,Misha Cohen,Gary Deng,Dawn Hershman,Matthew Mumber,Jane Perlmutter,Dugald Seely,Ananda Sen,Suzanna M Zick,Debu Tripathy,Society for Integrative Oncology,Donald Abrams,Lorenzo Cohen,Gustav J Dobos,Erika Erickson,Omer Kucuk,Jun Mao,Gregory Plotnikoff,Gabriel N Hortobagyi,Anna Wu,Musa Mayer,Eun-Sil Shelley Hwang
DOI: https://doi.org/10.1093/jncimonographs/lgu041
Abstract:Background: The majority of breast cancer patients use complementary and/or integrative therapies during and beyond cancer treatment to manage symptoms, prevent toxicities, and improve quality of life. Practice guidelines are needed to inform clinicians and patients about safe and effective therapies. Methods: Following the Institute of Medicine's guideline development process, a systematic review identified randomized controlled trials testing the use of integrative therapies for supportive care in patients receiving breast cancer treatment. Trials were included if the majority of participants had breast cancer and/or breast cancer patient results were reported separately, and outcomes were clinically relevant. Recommendations were organized by outcome and graded based upon a modified version of the US Preventive Services Task Force grading system. Results: The search (January 1, 1990-December 31, 2013) identified 4900 articles, of which 203 were eligible for analysis. Meditation, yoga, and relaxation with imagery are recommended for routine use for common conditions, including anxiety and mood disorders (Grade A). Stress management, yoga, massage, music therapy, energy conservation, and meditation are recommended for stress reduction, anxiety, depression, fatigue, and quality of life (Grade B). Many interventions (n = 32) had weaker evidence of benefit (Grade C). Some interventions (n = 7) were deemed unlikely to provide any benefit (Grade D). Notably, only one intervention, acetyl-l-carnitine for the prevention of taxane-induced neuropathy, was identified as likely harmful (Grade H) as it was found to increase neuropathy. The majority of intervention/modality combinations (n = 138) did not have sufficient evidence to form specific recommendations (Grade I). Conclusions: Specific integrative therapies can be recommended as evidence-based supportive care options during breast cancer treatment. Most integrative therapies require further investigation via well-designed controlled trials with meaningful outcomes.